You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NamePomalidomide
Accession NumberDB08910
TypeSmall Molecule
GroupsApproved
DescriptionPomalidomide, an analogue of thalidomide, is an immunomodulatory antineoplastic agent. FDA approved on February 8, 2013.
Structure
Thumb
SynonymsNot Available
External Identifiers
  • CC-4047
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
ImnovidCapsule4 mgOralCelgene Europe Ltd2013-08-05Not applicableEu
ImnovidCapsule1 mgOralCelgene Europe Ltd2013-08-05Not applicableEu
ImnovidCapsule2 mgOralCelgene Europe Ltd2013-08-05Not applicableEu
ImnovidCapsule3 mgOralCelgene Europe Ltd2013-08-05Not applicableEu
PomalystCapsule1 mgOralCelgene Inc2014-02-24Not applicableCanada
PomalystCapsule4 mg/1OralCelgene Corporation2013-02-18Not applicableUs
PomalystCapsule1 mg/1OralCelgene Corporation2013-02-18Not applicableUs
PomalystCapsule2 mgOralCelgene Inc2014-02-24Not applicableCanada
PomalystCapsule2 mg/1OralCelgene Corporation2013-02-18Not applicableUs
PomalystCapsule3 mgOralCelgene Inc2014-02-24Not applicableCanada
PomalystCapsule3 mg/1OralCelgene Corporation2013-02-18Not applicableUs
PomalystCapsule4 mgOralCelgene Inc2014-02-24Not applicableCanada
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
ImnovidNot Available
Brand mixturesNot Available
SaltsNot Available
Categories
UNIID2UX06XLB5
CAS number19171-19-8
WeightAverage: 273.2441
Monoisotopic: 273.074955855
Chemical FormulaC13H11N3O4
InChI KeyUVSMNLNDYGZFPF-UHFFFAOYNA-N
InChI
InChI=1/C13H11N3O4/c14-7-3-1-2-6-10(7)13(20)16(12(6)19)8-4-5-9(17)15-11(8)18/h1-3,8H,4-5,14H2,(H,15,17,18)
IUPAC Name
4-amino-2-(2,6-dioxopiperidin-3-yl)-2,3-dihydro-1H-isoindole-1,3-dione
SMILES
NC1=CC=CC2=C1C(=O)N(C1CCC(=O)NC1=O)C2=O
Pharmacology
IndicationPomalidomide is indicated for patients with multiple myeloma who have received at least two prior therapies including lenalidomide and bortezomib and have demonstrated disease progression on or within 60 days of completion of the last therapy.
Structured Indications
PharmacodynamicsPomalidomide is more potent than thalidomide (100-times) and lenalidomide (10-times).
Mechanism of actionPromalidomide is an immunomodulatory agent with antineoplastic activity. It is shown to inhibit the proliferation and induce apoptosis of various tumour cells. Furthermore, promalidomide enhances T cell and natural killer (NK) cell-mediated immunity and inhibited the production of pro-inflammatory cytokines, like TNF-alpha or IL-6, by monocytes. The primary target of promalidomide is thought to be the protein cereblon. It binds to this target and inhibits ubiquitin ligase activity. It is also a transcriptional inhibitor of COX2.
TargetKindPharmacological actionActionsOrganismUniProt ID
Protein cereblonProteinyes
inhibitor
HumanQ96SW2 details
Tumor necrosis factorProteinyes
inhibitor
HumanP01375 details
Prostaglandin G/H synthase 2Proteinyes
inhibitor
HumanP35354 details
Related Articles
AbsorptionPomalidomide is generally well absorbed. The major circulating component is the parent compound. Tmax, single oral dose = 2 -3 hours. When 4 mg of promalidomide is given to patients with multiple myeloma, the steady-state pharmacokinetic parameters are as follows: AUC(T) = 400 ng.hr/mL; Cmax = 75 ng/mL. Promalidomide accumulates following multiple doses.
Volume of distribution

Mean apparent volume of distribution (Vd/F), steady-state = 62 – 138 L

Protein binding12-44% protein bound. It is not concentration dependent.
Metabolism

Promalidomide is hepatically metabolized by CYP1A2 and CYP3A4. The metabolites are 26-fold less active than the parent compound. Minor contributions from CYP2C19 and CYP2D6 have been observed in vitro.

Route of eliminationWhen a single oral dose (2mg) is given to healthy subjects, 73% of the dose was eliminated in urine. 15% of the dose was eliminated in feces. 2% and 8% of the dose eliminated unchanged as pomalidomide in urine and feces, respectively.
Half lifeHealthy subjects = 9.4 hours; Multiple myeloma patients = 7.5 hours.
Clearance

Total body clearance = 7-10 L/hour

ToxicityMost common adverse reactions (≥30%) included fatigue and asthenia, neutropenia, anemia, constipation, nausea, diarrhea, dyspnea, upper-respiratory tract infections, back pain and pyrexia.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
1,1,1,2 TetrafluoroethaneThe risk or severity of adverse effects can be increased when Pomalidomide is combined with 1,1,1,2 Tetrafluoroethane.Investigational
7-NitroindazoleThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Pomalidomide.Experimental
AbirateroneThe serum concentration of Pomalidomide can be increased when it is combined with Abiraterone.Approved
AcepromazineThe risk or severity of adverse effects can be increased when Acepromazine is combined with Pomalidomide.Approved, Vet Approved
AceprometazineThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Pomalidomide.Approved
AcetaminophenThe serum concentration of Pomalidomide can be increased when it is combined with Acetaminophen.Approved
AcetyldigitoxinAcetyldigitoxin may decrease the cardiotoxic activities of Pomalidomide.Approved
adipiplonThe risk or severity of adverse effects can be increased when adipiplon is combined with Pomalidomide.Investigational
AfatinibThe serum concentration of Pomalidomide can be increased when it is combined with Afatinib.Approved
AgomelatineThe risk or severity of adverse effects can be increased when Agomelatine is combined with Pomalidomide.Approved, Investigational
AlbendazoleThe serum concentration of Pomalidomide can be increased when it is combined with Albendazole.Approved, Vet Approved
AldosteroneThe serum concentration of Pomalidomide can be decreased when it is combined with Aldosterone.Experimental
AlectinibThe serum concentration of Pomalidomide can be increased when it is combined with Alectinib.Approved
AlfaxaloneThe risk or severity of adverse effects can be increased when Alfaxalone is combined with Pomalidomide.Vet Approved
AlfentanilThe serum concentration of Pomalidomide can be increased when it is combined with Alfentanil.Approved, Illicit
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Alphacetylmethadol is combined with Pomalidomide.Experimental, Illicit
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Pomalidomide.Approved, Illicit, Investigational
ALT-110The risk or severity of adverse effects can be increased when Pomalidomide is combined with ALT-110.Investigational
AmantadineThe serum concentration of Pomalidomide can be increased when it is combined with Amantadine.Approved
Aminohippuric acidThe serum concentration of Pomalidomide can be increased when it is combined with Aminohippuric acid.Approved
AmiodaroneThe metabolism of Pomalidomide can be decreased when combined with Amiodarone.Approved, Investigational
AmisulprideThe risk or severity of adverse effects can be increased when Amisulpride is combined with Pomalidomide.Approved, Investigational
AmitriptylineThe serum concentration of Pomalidomide can be increased when it is combined with Amitriptyline.Approved
AmlodipineThe serum concentration of Pomalidomide can be increased when it is combined with Amlodipine.Approved
AmobarbitalThe risk or severity of adverse effects can be increased when Amobarbital is combined with Pomalidomide.Approved, Illicit
AmoxapineThe risk or severity of adverse effects can be increased when Amoxapine is combined with Pomalidomide.Approved
AmperozideThe risk or severity of adverse effects can be increased when Amperozide is combined with Pomalidomide.Experimental
AmprenavirThe serum concentration of Pomalidomide can be decreased when it is combined with Amprenavir.Approved
AmsacrineThe serum concentration of Pomalidomide can be increased when it is combined with Amsacrine.Approved
AnvirzelAnvirzel may decrease the cardiotoxic activities of Pomalidomide.Investigational
AprepitantThe serum concentration of Pomalidomide can be increased when it is combined with Aprepitant.Approved, Investigational
AripiprazoleThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Pomalidomide.Approved, Investigational
ArticaineThe risk or severity of adverse effects can be increased when Articaine is combined with Pomalidomide.Approved
AsenapineThe risk or severity of adverse effects can be increased when Asenapine is combined with Pomalidomide.Approved
AstemizoleThe serum concentration of Pomalidomide can be increased when it is combined with Astemizole.Approved, Withdrawn
AtazanavirThe metabolism of Pomalidomide can be decreased when combined with Atazanavir.Approved, Investigational
AtenololThe serum concentration of Pomalidomide can be increased when it is combined with Atenolol.Approved
AtomoxetineThe metabolism of Pomalidomide can be decreased when combined with Atomoxetine.Approved
AtorvastatinThe serum concentration of Pomalidomide can be increased when it is combined with Atorvastatin.Approved
AzaperoneThe risk or severity of adverse effects can be increased when Azaperone is combined with Pomalidomide.Vet Approved
AzelastinePomalidomide may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
AzelastineThe serum concentration of Pomalidomide can be increased when it is combined with Azelastine.Approved
AzithromycinThe serum concentration of Pomalidomide can be increased when it is combined with Azithromycin.Approved
BaclofenThe risk or severity of adverse effects can be increased when Baclofen is combined with Pomalidomide.Approved
BarbitalThe risk or severity of adverse effects can be increased when Barbital is combined with Pomalidomide.Illicit
BcgThe therapeutic efficacy of Bcg can be decreased when used in combination with Pomalidomide.Investigational
BenperidolThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Benperidol.Investigational
BenzocaineThe serum concentration of Pomalidomide can be increased when it is combined with Benzocaine.Approved
Benzyl alcoholThe risk or severity of adverse effects can be increased when Benzyl alcohol is combined with Pomalidomide.Approved
BepridilThe serum concentration of Pomalidomide can be increased when it is combined with Bepridil.Approved, Withdrawn
BevacizumabBevacizumab may increase the cardiotoxic activities of Pomalidomide.Approved, Investigational
BexaroteneThe serum concentration of Pomalidomide can be decreased when it is combined with Bexarotene.Approved, Investigational
BiperidenThe serum concentration of Pomalidomide can be increased when it is combined with Biperiden.Approved
BoceprevirThe metabolism of Pomalidomide can be decreased when combined with Boceprevir.Approved
BortezomibThe metabolism of Pomalidomide can be decreased when combined with Bortezomib.Approved, Investigational
BosentanThe serum concentration of Pomalidomide can be decreased when it is combined with Bosentan.Approved, Investigational
BosutinibThe serum concentration of Pomalidomide can be increased when it is combined with Bosutinib.Approved
BrexpiprazoleThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Brexpiprazole.Approved
BrimonidineThe risk or severity of adverse effects can be increased when Brimonidine is combined with Pomalidomide.Approved
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Pomalidomide.Approved
BromazepamThe risk or severity of adverse effects can be increased when Bromazepam is combined with Pomalidomide.Approved, Illicit
BromocriptineThe serum concentration of Pomalidomide can be increased when it is combined with Bromocriptine.Approved, Investigational
BrompheniramineThe risk or severity of adverse effects can be increased when Brompheniramine is combined with Pomalidomide.Approved
BrotizolamThe risk or severity of adverse effects can be increased when Brotizolam is combined with Pomalidomide.Approved, Withdrawn
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Pomalidomide.Approved, Investigational
BuprenorphinePomalidomide may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BuspironeThe serum concentration of Pomalidomide can be increased when it is combined with Buspirone.Approved, Investigational
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Pomalidomide.Approved, Illicit
ButacaineThe risk or severity of adverse effects can be increased when Butacaine is combined with Pomalidomide.Vet Approved
ButalbitalThe risk or severity of adverse effects can be increased when Butalbital is combined with Pomalidomide.Approved, Illicit
ButambenThe risk or severity of adverse effects can be increased when Butamben is combined with Pomalidomide.Approved
ButethalThe risk or severity of adverse effects can be increased when Butethal is combined with Pomalidomide.Approved, Illicit
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Pomalidomide.Approved, Illicit, Vet Approved
CabazitaxelThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Pomalidomide.Approved
CaffeineThe serum concentration of Pomalidomide can be increased when it is combined with Caffeine.Approved
CanagliflozinThe serum concentration of Pomalidomide can be increased when it is combined with Canagliflozin.Approved
CandesartanThe serum concentration of Pomalidomide can be increased when it is combined with Candesartan.Approved
CaptoprilThe serum concentration of Pomalidomide can be increased when it is combined with Captopril.Approved
CarbamazepineThe metabolism of Pomalidomide can be increased when combined with Carbamazepine.Approved, Investigational
CarbinoxamineThe risk or severity of adverse effects can be increased when Carbinoxamine is combined with Pomalidomide.Approved
CarfentanilThe risk or severity of adverse effects can be increased when Carfentanil is combined with Pomalidomide.Illicit, Vet Approved
CarisoprodolThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Pomalidomide.Approved
CarvedilolThe serum concentration of Pomalidomide can be increased when it is combined with Carvedilol.Approved, Investigational
CaspofunginThe serum concentration of Pomalidomide can be increased when it is combined with Caspofungin.Approved
CDX-110The risk or severity of adverse effects can be increased when Pomalidomide is combined with CDX-110.Investigational
CeritinibThe serum concentration of Pomalidomide can be increased when it is combined with Ceritinib.Approved
CetirizineThe risk or severity of adverse effects can be increased when Cetirizine is combined with Pomalidomide.Approved
Chloral hydrateThe risk or severity of adverse effects can be increased when Chloral hydrate is combined with Pomalidomide.Approved, Illicit, Vet Approved
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Pomalidomide.Approved, Illicit
ChlormezanoneThe risk or severity of adverse effects can be increased when Chlormezanone is combined with Pomalidomide.Approved, Withdrawn
ChloroprocaineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Pomalidomide.Approved
ChloroquineThe serum concentration of Pomalidomide can be increased when it is combined with Chloroquine.Approved, Vet Approved
ChlorphenamineThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Pomalidomide.Approved
ChlorpromazineThe serum concentration of Pomalidomide can be increased when it is combined with Chlorpromazine.Approved, Vet Approved
ChlorpropamideThe serum concentration of Pomalidomide can be increased when it is combined with Chlorpropamide.Approved
ChlorprothixeneThe serum concentration of Pomalidomide can be increased when it is combined with Chlorprothixene.Approved, Withdrawn
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Pomalidomide.Approved
CholesterolThe serum concentration of Pomalidomide can be increased when it is combined with Cholesterol.Experimental
Cholic AcidThe serum concentration of Pomalidomide can be decreased when it is combined with Cholic Acid.Approved
CilazaprilThe serum concentration of Pomalidomide can be increased when it is combined with Cilazapril.Approved
CimetidineThe serum concentration of Pomalidomide can be decreased when it is combined with Cimetidine.Approved
CinchocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Pomalidomide.Approved, Vet Approved
CiprofloxacinThe serum concentration of Pomalidomide can be increased when it is combined with Ciprofloxacin.Approved, Investigational
CitalopramThe serum concentration of Pomalidomide can be increased when it is combined with Citalopram.Approved
ClarithromycinThe metabolism of Pomalidomide can be decreased when combined with Clarithromycin.Approved
ClemastineThe metabolism of Pomalidomide can be decreased when combined with Clemastine.Approved
ClidiniumThe risk or severity of adverse effects can be increased when Clidinium is combined with Pomalidomide.Approved
ClobazamThe risk or severity of adverse effects can be increased when Clobazam is combined with Pomalidomide.Approved, Illicit
ClofazimineThe serum concentration of Pomalidomide can be increased when it is combined with Clofazimine.Approved, Investigational
clomethiazoleThe risk or severity of adverse effects can be increased when clomethiazole is combined with Pomalidomide.Investigational
ClomipramineThe serum concentration of Pomalidomide can be increased when it is combined with Clomipramine.Approved, Vet Approved
ClonazepamThe risk or severity of adverse effects can be increased when Clonazepam is combined with Pomalidomide.Approved, Illicit
ClonidineThe risk or severity of adverse effects can be increased when Clonidine is combined with Pomalidomide.Approved
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Pomalidomide.Approved, Illicit
ClotrimazoleThe metabolism of Pomalidomide can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Clozapine.Approved
CobicistatThe metabolism of Pomalidomide can be decreased when combined with Cobicistat.Approved
CocaineThe risk or severity of adverse effects can be increased when Cocaine is combined with Pomalidomide.Approved, Illicit
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Pomalidomide.Approved, Illicit
ColchicineThe serum concentration of Pomalidomide can be increased when it is combined with Colchicine.Approved
ColforsinThe serum concentration of Pomalidomide can be increased when it is combined with Colforsin.Experimental
ConivaptanThe serum concentration of Pomalidomide can be increased when it is combined with Conivaptan.Approved, Investigational
CrizotinibThe metabolism of Pomalidomide can be decreased when combined with Crizotinib.Approved
CyclizineThe risk or severity of adverse effects can be increased when Cyclizine is combined with Pomalidomide.Approved
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Pomalidomide.Approved
CyclophosphamideCyclophosphamide may increase the cardiotoxic activities of Pomalidomide.Approved, Investigational
CyclosporineThe metabolism of Pomalidomide can be decreased when combined with Cyclosporine.Approved, Investigational, Vet Approved
CyproheptadineThe risk or severity of adverse effects can be increased when Cyproheptadine is combined with Pomalidomide.Approved
Cyproterone acetateThe serum concentration of Pomalidomide can be decreased when it is combined with Cyproterone acetate.Approved, Investigational
DabrafenibThe serum concentration of Pomalidomide can be decreased when it is combined with Dabrafenib.Approved
DaclatasvirThe serum concentration of Pomalidomide can be increased when it is combined with Daclatasvir.Approved
DactinomycinThe serum concentration of Pomalidomide can be increased when it is combined with Dactinomycin.Approved
DantroleneThe risk or severity of adverse effects can be increased when Dantrolene is combined with Pomalidomide.Approved
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Pomalidomide.Approved
DapoxetineThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Dapoxetine.Investigational
DarunavirThe metabolism of Pomalidomide can be decreased when combined with Darunavir.Approved
DasatinibThe serum concentration of Pomalidomide can be increased when it is combined with Dasatinib.Approved, Investigational
DaunorubicinThe serum concentration of Pomalidomide can be decreased when it is combined with Daunorubicin.Approved
DeferasiroxThe serum concentration of Pomalidomide can be decreased when it is combined with Deferasirox.Approved, Investigational
DelavirdineThe metabolism of Pomalidomide can be decreased when combined with Delavirdine.Approved
DenosumabThe risk or severity of adverse effects can be increased when Denosumab is combined with Pomalidomide.Approved
deramciclaneThe risk or severity of adverse effects can be increased when deramciclane is combined with Pomalidomide.Investigational
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Pomalidomide.Approved
DesipramineThe serum concentration of Pomalidomide can be increased when it is combined with Desipramine.Approved
DeslanosideDeslanoside may decrease the cardiotoxic activities of Pomalidomide.Approved
DesloratadineThe serum concentration of Pomalidomide can be increased when it is combined with Desloratadine.Approved, Investigational
DesvenlafaxineThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Desvenlafaxine.Approved
DetomidineThe risk or severity of adverse effects can be increased when Detomidine is combined with Pomalidomide.Vet Approved
DexamethasoneThe serum concentration of Pomalidomide can be decreased when it is combined with Dexamethasone.Approved, Investigational, Vet Approved
DexbrompheniramineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Pomalidomide.Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Pomalidomide.Approved, Vet Approved
DextromethorphanThe serum concentration of Pomalidomide can be increased when it is combined with Dextromethorphan.Approved
DextromoramideThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Pomalidomide.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Pomalidomide.Approved, Illicit, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Dezocine is combined with Pomalidomide.Approved
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Pomalidomide.Approved, Illicit, Vet Approved
DiclofenacThe serum concentration of Pomalidomide can be increased when it is combined with Diclofenac.Approved, Vet Approved
DifenoxinThe risk or severity of adverse effects can be increased when Difenoxin is combined with Pomalidomide.Approved, Illicit
DigitoxinDigitoxin may decrease the cardiotoxic activities of Pomalidomide.Approved
DigoxinDigoxin may decrease the cardiotoxic activities of Pomalidomide.Approved
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Pomalidomide.Approved, Illicit
DihydroergotamineThe metabolism of Pomalidomide can be decreased when combined with Dihydroergotamine.Approved
DihydroetorphineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Pomalidomide.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Pomalidomide.Experimental, Illicit
DiltiazemThe metabolism of Pomalidomide can be decreased when combined with Diltiazem.Approved
DimenhydrinateThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Pomalidomide.Approved
DiphenhydramineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Pomalidomide.Approved
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Pomalidomide.Approved, Illicit
DipyridamoleThe serum concentration of Pomalidomide can be increased when it is combined with Dipyridamole.Approved
DocetaxelThe risk or severity of adverse effects can be increased when Docetaxel is combined with Pomalidomide.Approved, Investigational
DoramectinThe risk or severity of adverse effects can be increased when Doramectin is combined with Pomalidomide.Vet Approved
DoxazosinThe serum concentration of Pomalidomide can be increased when it is combined with Doxazosin.Approved
DoxepinThe serum concentration of Pomalidomide can be increased when it is combined with Doxepin.Approved
DoxorubicinThe serum concentration of Pomalidomide can be decreased when it is combined with Doxorubicin.Approved, Investigational
DoxycyclineThe metabolism of Pomalidomide can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Pomalidomide.Approved, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when DPDPE is combined with Pomalidomide.Investigational
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Pomalidomide.Approved, Illicit
DronedaroneThe metabolism of Pomalidomide can be decreased when combined with Dronedarone.Approved
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Pomalidomide.Approved, Vet Approved
DrotebanolThe risk or severity of adverse effects can be increased when Drotebanol is combined with Pomalidomide.Experimental, Illicit
DuloxetineThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Duloxetine.Approved
DyclonineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Pomalidomide.Approved
EcgonineThe risk or severity of adverse effects can be increased when Ecgonine is combined with Pomalidomide.Experimental, Illicit
ECGONINE METHYL ESTERThe risk or severity of adverse effects can be increased when ECGONINE METHYL ESTER is combined with Pomalidomide.Experimental
EcopipamThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Ecopipam.Investigational
EfavirenzThe serum concentration of Pomalidomide can be decreased when it is combined with Efavirenz.Approved, Investigational
ElbasvirThe serum concentration of Pomalidomide can be increased when it is combined with Elbasvir.Approved
EnalaprilThe serum concentration of Pomalidomide can be increased when it is combined with Enalapril.Approved, Vet Approved
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Pomalidomide.Approved, Vet Approved
EntacaponeThe risk or severity of adverse effects can be increased when Entacapone is combined with Pomalidomide.Approved, Investigational
EnzalutamideThe serum concentration of Pomalidomide can be decreased when it is combined with Enzalutamide.Approved
ErgonovineThe serum concentration of Pomalidomide can be increased when it is combined with Ergonovine.Approved
ErgotamineThe serum concentration of Pomalidomide can be increased when it is combined with Ergotamine.Approved
ErythromycinThe metabolism of Pomalidomide can be decreased when combined with Erythromycin.Approved, Vet Approved
EscitalopramThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Escitalopram.Approved, Investigational
Eslicarbazepine acetateThe serum concentration of Pomalidomide can be decreased when it is combined with Eslicarbazepine acetate.Approved
EstazolamThe risk or severity of adverse effects can be increased when Estazolam is combined with Pomalidomide.Approved, Illicit
EstramustineThe serum concentration of Pomalidomide can be increased when it is combined with Estramustine.Approved
EstriolThe serum concentration of Pomalidomide can be decreased when it is combined with Estriol.Approved, Vet Approved
EstroneThe serum concentration of Pomalidomide can be decreased when it is combined with Estrone.Approved
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Pomalidomide.Approved
EthanolPomalidomide may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Pomalidomide.Approved, Illicit, Withdrawn
EthosuximideThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Pomalidomide.Approved
EthotoinThe risk or severity of adverse effects can be increased when Ethotoin is combined with Pomalidomide.Approved
Ethyl carbamateThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Pomalidomide.Withdrawn
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Pomalidomide.Approved, Illicit
EthylmorphineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Pomalidomide.Approved, Illicit
EtidocaineThe risk or severity of adverse effects can be increased when Etidocaine is combined with Pomalidomide.Approved
EtifoxineThe risk or severity of adverse effects can be increased when Etifoxine is combined with Pomalidomide.Withdrawn
EtizolamThe risk or severity of adverse effects can be increased when Etizolam is combined with Pomalidomide.Approved
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Pomalidomide.Approved
EtoperidoneThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Etoperidone.Approved
EtoposideThe serum concentration of Pomalidomide can be increased when it is combined with Etoposide.Approved
EtorphineThe risk or severity of adverse effects can be increased when Etorphine is combined with Pomalidomide.Illicit, Vet Approved
EtravirineThe serum concentration of Pomalidomide can be decreased when it is combined with Etravirine.Approved
EzogabineThe risk or severity of adverse effects can be increased when Ezogabine is combined with Pomalidomide.Approved
FelbamateThe risk or severity of adverse effects can be increased when Felbamate is combined with Pomalidomide.Approved
FelodipineThe serum concentration of Pomalidomide can be increased when it is combined with Felodipine.Approved, Investigational
FencamfamineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Pomalidomide.Approved, Illicit, Withdrawn
FentanylThe serum concentration of Pomalidomide can be increased when it is combined with Fentanyl.Approved, Illicit, Investigational, Vet Approved
FexofenadineThe serum concentration of Pomalidomide can be increased when it is combined with Fexofenadine.Approved
FidaxomicinThe serum concentration of Pomalidomide can be increased when it is combined with Fidaxomicin.Approved
FingolimodPomalidomide may increase the immunosuppressive activities of Fingolimod.Approved, Investigational
FlibanserinThe risk or severity of adverse effects can be increased when Flibanserin is combined with Pomalidomide.Approved
FluconazoleThe metabolism of Pomalidomide can be decreased when combined with Fluconazole.Approved
FludiazepamThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Pomalidomide.Approved, Illicit
FlunarizineThe risk or severity of adverse effects can be increased when Flunarizine is combined with Pomalidomide.Approved
FlunitrazepamThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Pomalidomide.Approved, Illicit
FluoxetineThe serum concentration of Pomalidomide can be increased when it is combined with Fluoxetine.Approved, Vet Approved
FlupentixolThe serum concentration of Pomalidomide can be increased when it is combined with Flupentixol.Approved, Withdrawn
FluphenazineThe serum concentration of Pomalidomide can be increased when it is combined with Fluphenazine.Approved
FlurazepamThe serum concentration of Pomalidomide can be increased when it is combined with Flurazepam.Approved, Illicit
FluspirileneThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Pomalidomide.Approved
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Fluticasone Propionate is combined with Pomalidomide.Approved
FluvoxamineThe serum concentration of Pomalidomide can be increased when it is combined with Fluvoxamine.Approved, Investigational
FosamprenavirThe metabolism of Pomalidomide can be decreased when combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Pomalidomide can be increased when it is combined with Fosaprepitant.Approved
FosphenytoinThe metabolism of Pomalidomide can be increased when combined with Fosphenytoin.Approved
FospropofolThe risk or severity of adverse effects can be increased when Fospropofol is combined with Pomalidomide.Approved, Illicit
Fusidic AcidThe serum concentration of Pomalidomide can be increased when it is combined with Fusidic Acid.Approved
G17DTThe risk or severity of adverse effects can be increased when Pomalidomide is combined with G17DT.Investigational
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Pomalidomide.Approved, Investigational
gabapentin enacarbilThe risk or severity of adverse effects can be increased when gabapentin enacarbil is combined with Pomalidomide.Approved
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Pomalidomide.Approved, Illicit
GefitinibThe serum concentration of Pomalidomide can be increased when it is combined with Gefitinib.Approved, Investigational
GenisteinThe serum concentration of Pomalidomide can be increased when it is combined with Genistein.Investigational
GepironeThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Gepirone.Investigational
GI-5005The risk or severity of adverse effects can be increased when Pomalidomide is combined with GI-5005.Investigational
GlutethimideThe risk or severity of adverse effects can be increased when Glutethimide is combined with Pomalidomide.Approved, Illicit
GlyburideThe serum concentration of Pomalidomide can be increased when it is combined with Glyburide.Approved
GlycerolThe serum concentration of Pomalidomide can be increased when it is combined with Glycerol.Experimental
Gramicidin DThe serum concentration of Pomalidomide can be increased when it is combined with Gramicidin D.Approved
GrepafloxacinThe serum concentration of Pomalidomide can be increased when it is combined with Grepafloxacin.Withdrawn
GuanfacineThe risk or severity of adverse effects can be increased when Guanfacine is combined with Pomalidomide.Approved, Investigational
HalazepamThe risk or severity of adverse effects can be increased when Halazepam is combined with Pomalidomide.Approved, Illicit, Withdrawn
HaloperidolThe serum concentration of Pomalidomide can be increased when it is combined with Haloperidol.Approved
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Pomalidomide.Approved, Vet Approved
HeroinThe risk or severity of adverse effects can be increased when Heroin is combined with Pomalidomide.Approved, Illicit
HexobarbitalThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Pomalidomide.Approved
HydrocodonePomalidomide may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
HydrocortisoneThe serum concentration of Pomalidomide can be increased when it is combined with Hydrocortisone.Approved, Vet Approved
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Pomalidomide.Approved, Illicit
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Pomalidomide.Approved
IdelalisibThe serum concentration of Pomalidomide can be increased when it is combined with Idelalisib.Approved
IloperidoneThe risk or severity of adverse effects can be increased when Iloperidone is combined with Pomalidomide.Approved
ImatinibThe metabolism of Pomalidomide can be decreased when combined with Imatinib.Approved
ImipramineThe serum concentration of Pomalidomide can be increased when it is combined with Imipramine.Approved
IndalpineThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Indalpine.Investigational, Withdrawn
IndinavirThe metabolism of Pomalidomide can be decreased when combined with Indinavir.Approved
IndomethacinThe serum concentration of Pomalidomide can be increased when it is combined with Indomethacin.Approved, Investigational
INGN 201The risk or severity of adverse effects can be increased when Pomalidomide is combined with INGN 201.Investigational
INGN 225The risk or severity of adverse effects can be increased when Pomalidomide is combined with INGN 225.Investigational
IsavuconazoniumThe metabolism of Pomalidomide can be decreased when combined with Isavuconazonium.Approved, Investigational
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Pomalidomide.Approved, Vet Approved
IsradipineThe metabolism of Pomalidomide can be decreased when combined with Isradipine.Approved
ItraconazoleThe metabolism of Pomalidomide can be decreased when combined with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Pomalidomide can be increased when it is combined with Ivacaftor.Approved
IvermectinThe serum concentration of Pomalidomide can be increased when it is combined with Ivermectin.Approved, Vet Approved
KetamineThe serum concentration of Pomalidomide can be increased when it is combined with Ketamine.Approved, Vet Approved
KetazolamThe risk or severity of adverse effects can be increased when Ketazolam is combined with Pomalidomide.Approved
KetobemidoneThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Pomalidomide.Approved
KetoconazoleThe metabolism of Pomalidomide can be decreased when combined with Ketoconazole.Approved, Investigational
LamotrigineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Pomalidomide.Approved, Investigational
LansoprazoleThe serum concentration of Pomalidomide can be increased when it is combined with Lansoprazole.Approved, Investigational
LapatinibThe serum concentration of Pomalidomide can be increased when it is combined with Lapatinib.Approved, Investigational
LeflunomideThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Leflunomide.Approved, Investigational
LevetiracetamThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Pomalidomide.Approved, Investigational
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Pomalidomide.Approved
LevocabastineThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Levocabastine.Approved
LevocetirizineThe risk or severity of adverse effects can be increased when Levocetirizine is combined with Pomalidomide.Approved
LevodopaThe risk or severity of adverse effects can be increased when Levodopa is combined with Pomalidomide.Approved
LevofloxacinThe serum concentration of Pomalidomide can be increased when it is combined with Levofloxacin.Approved, Investigational
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Pomalidomide.Approved
LevomilnacipranThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Levomilnacipran.Approved
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Pomalidomide.Approved
LevothyroxineThe serum concentration of Pomalidomide can be decreased when it is combined with Levothyroxine.Approved
LidocaineThe serum concentration of Pomalidomide can be increased when it is combined with Lidocaine.Approved, Vet Approved
LiothyronineThe serum concentration of Pomalidomide can be decreased when it is combined with Liothyronine.Approved, Vet Approved
LiotrixThe serum concentration of Pomalidomide can be decreased when it is combined with Liotrix.Approved
LisinoprilThe serum concentration of Pomalidomide can be increased when it is combined with Lisinopril.Approved, Investigational
LithiumThe risk or severity of adverse effects can be increased when Lithium is combined with Pomalidomide.Approved
LofentanilThe risk or severity of adverse effects can be increased when Lofentanil is combined with Pomalidomide.Illicit
LomitapideThe serum concentration of Pomalidomide can be increased when it is combined with Lomitapide.Approved
LoperamideThe serum concentration of Pomalidomide can be increased when it is combined with Loperamide.Approved
LopinavirThe metabolism of Pomalidomide can be decreased when combined with Lopinavir.Approved
LoratadineThe serum concentration of Pomalidomide can be increased when it is combined with Loratadine.Approved
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Pomalidomide.Approved
LosartanThe serum concentration of Pomalidomide can be increased when it is combined with Losartan.Approved
LovastatinThe metabolism of Pomalidomide can be decreased when combined with Lovastatin.Approved, Investigational
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Pomalidomide.Approved
Lu AA21004The risk or severity of adverse effects can be increased when Lu AA21004 is combined with Pomalidomide.Investigational
LuliconazoleThe serum concentration of Pomalidomide can be increased when it is combined with Luliconazole.Approved
LumacaftorThe serum concentration of Pomalidomide can be decreased when it is combined with Lumacaftor.Approved
LurasidoneThe risk or severity of adverse effects can be increased when Lurasidone is combined with Pomalidomide.Approved
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Pomalidomide.Approved, Vet Approved
MaprotilineThe serum concentration of Pomalidomide can be increased when it is combined with Maprotiline.Approved
MebendazoleThe serum concentration of Pomalidomide can be increased when it is combined with Mebendazole.Approved, Vet Approved
MeclizineThe risk or severity of adverse effects can be increased when Meclizine is combined with Pomalidomide.Approved
MedetomidineThe risk or severity of adverse effects can be increased when Medetomidine is combined with Pomalidomide.Vet Approved
MefloquineThe serum concentration of Pomalidomide can be increased when it is combined with Mefloquine.Approved
Megestrol acetateThe serum concentration of Pomalidomide can be increased when it is combined with Megestrol acetate.Approved, Vet Approved
MelatoninThe risk or severity of adverse effects can be increased when Melatonin is combined with Pomalidomide.Approved, Nutraceutical, Vet Approved
MelperoneThe risk or severity of adverse effects can be increased when Melperone is combined with Pomalidomide.Approved
MepivacaineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Pomalidomide.Approved, Vet Approved
MeprobamateThe serum concentration of Pomalidomide can be increased when it is combined with Meprobamate.Approved, Illicit
MesoridazineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Pomalidomide.Approved
MetamizoleThe risk or severity of adverse effects can be increased when Metamizole is combined with Pomalidomide.Withdrawn
MetaxaloneThe risk or severity of adverse effects can be increased when Metaxalone is combined with Pomalidomide.Approved
MethadoneThe serum concentration of Pomalidomide can be increased when it is combined with Methadone.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Methadyl Acetate is combined with Pomalidomide.Approved, Illicit
MethapyrileneThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Pomalidomide.Withdrawn
MethaqualoneThe risk or severity of adverse effects can be increased when Methaqualone is combined with Pomalidomide.Illicit, Withdrawn
MethocarbamolThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Pomalidomide.Approved, Vet Approved
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Pomalidomide.Approved
MethotrimeprazinePomalidomide may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
MethoxyfluraneThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Pomalidomide.Approved, Vet Approved
MethsuximideThe risk or severity of adverse effects can be increased when Methsuximide is combined with Pomalidomide.Approved
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Pomalidomide.Approved
MetoprololThe serum concentration of Pomalidomide can be increased when it is combined with Metoprolol.Approved, Investigational
MetyrosinePomalidomide may increase the sedative activities of Metyrosine.Approved
MexiletineThe serum concentration of Pomalidomide can be increased when it is combined with Mexiletine.Approved
MibefradilThe serum concentration of Pomalidomide can be increased when it is combined with Mibefradil.Withdrawn
MiconazoleThe serum concentration of Pomalidomide can be increased when it is combined with Miconazole.Approved, Investigational, Vet Approved
MidazolamThe serum concentration of Pomalidomide can be decreased when it is combined with Midazolam.Approved, Illicit
MifepristoneThe serum concentration of Pomalidomide can be increased when it is combined with Mifepristone.Approved, Investigational
MilnacipranThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Milnacipran.Approved
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Pomalidomide.Approved, Investigational
MirtazapinePomalidomide may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
MitomycinThe serum concentration of Pomalidomide can be increased when it is combined with Mitomycin.Approved
MitotaneThe serum concentration of Pomalidomide can be decreased when it is combined with Mitotane.Approved
MitoxantroneThe serum concentration of Pomalidomide can be decreased when it is combined with Mitoxantrone.Approved, Investigational
ModafinilThe serum concentration of Pomalidomide can be decreased when it is combined with Modafinil.Approved, Investigational
MolindoneThe risk or severity of adverse effects can be increased when Molindone is combined with Pomalidomide.Approved
MorphineThe serum concentration of Pomalidomide can be increased when it is combined with Morphine.Approved, Investigational
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Pomalidomide.Approved, Investigational
NafcillinThe serum concentration of Pomalidomide can be decreased when it is combined with Nafcillin.Approved
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Pomalidomide.Approved
NaltrexoneThe serum concentration of Pomalidomide can be increased when it is combined with Naltrexone.Approved, Investigational, Vet Approved
NaringeninThe serum concentration of Pomalidomide can be increased when it is combined with Naringenin.Experimental
NatalizumabThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Natalizumab.Approved, Investigational
NefazodoneThe metabolism of Pomalidomide can be decreased when combined with Nefazodone.Approved, Withdrawn
NelfinavirThe metabolism of Pomalidomide can be decreased when combined with Nelfinavir.Approved
NeostigmineThe serum concentration of Pomalidomide can be increased when it is combined with Neostigmine.Approved, Vet Approved
NetupitantThe serum concentration of Pomalidomide can be increased when it is combined with Netupitant.Approved
NevirapineThe metabolism of Pomalidomide can be increased when combined with Nevirapine.Approved
NicardipineThe serum concentration of Pomalidomide can be increased when it is combined with Nicardipine.Approved
NifedipineThe serum concentration of Pomalidomide can be decreased when it is combined with Nifedipine.Approved
NilotinibThe metabolism of Pomalidomide can be decreased when combined with Nilotinib.Approved, Investigational
NisoldipineThe serum concentration of Pomalidomide can be increased when it is combined with Nisoldipine.Approved
NitrazepamThe serum concentration of Pomalidomide can be increased when it is combined with Nitrazepam.Approved
NitrendipineThe serum concentration of Pomalidomide can be increased when it is combined with Nitrendipine.Approved
Nitrous oxideThe risk or severity of adverse effects can be increased when Nitrous oxide is combined with Pomalidomide.Approved, Vet Approved
NorethisteroneThe serum concentration of Pomalidomide can be decreased when it is combined with Norethisterone.Approved
NormethadoneThe risk or severity of adverse effects can be increased when Normethadone is combined with Pomalidomide.Approved, Illicit
NortriptylineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Pomalidomide.Approved
OlanzapineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Pomalidomide.Approved, Investigational
OlaparibThe metabolism of Pomalidomide can be decreased when combined with Olaparib.Approved
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Pomalidomide.Approved
OmeprazoleThe serum concentration of Pomalidomide can be increased when it is combined with Omeprazole.Approved, Investigational, Vet Approved
OndansetronThe risk or severity of adverse effects can be increased when Ondansetron is combined with Pomalidomide.Approved
OpiumThe risk or severity of adverse effects can be increased when Opium is combined with Pomalidomide.Approved, Illicit
OrphenadrinePomalidomide may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
OsanetantThe risk or severity of adverse effects can be increased when Osanetant is combined with Pomalidomide.Investigational
OsimertinibThe serum concentration of Pomalidomide can be increased when it is combined with Osimertinib.Approved
OuabainOuabain may decrease the cardiotoxic activities of Pomalidomide.Approved
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Pomalidomide.Approved
OxetacaineThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Oxetacaine.Investigational
OxprenololThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Pomalidomide.Approved
OxybuprocaineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Pomalidomide.Approved
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Pomalidomide.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Pomalidomide.Approved, Investigational, Vet Approved
P-NitrophenolThe serum concentration of Pomalidomide can be increased when it is combined with P-Nitrophenol.Experimental
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Pomalidomide.Approved, Vet Approved
PalbociclibThe serum concentration of Pomalidomide can be increased when it is combined with Palbociclib.Approved
PaliperidoneThe risk or severity of adverse effects can be increased when Paliperidone is combined with Pomalidomide.Approved
Palmitic AcidThe serum concentration of Pomalidomide can be increased when it is combined with Palmitic Acid.Experimental
PantoprazoleThe serum concentration of Pomalidomide can be increased when it is combined with Pantoprazole.Approved
ParaldehydePomalidomide may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.Approved
ParoxetineThe serum concentration of Pomalidomide can be increased when it is combined with Paroxetine.Approved, Investigational
Peginterferon alfa-2bThe serum concentration of Pomalidomide can be increased when it is combined with Peginterferon alfa-2b.Approved
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Pomalidomide.Approved, Vet Approved
PentobarbitalThe metabolism of Pomalidomide can be increased when combined with Pentobarbital.Approved, Vet Approved
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Pomalidomide.Approved
PerazineThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Perazine.Investigational
PerindoprilThe serum concentration of Pomalidomide can be increased when it is combined with Perindopril.Approved
PerospironeThe risk or severity of adverse effects can be increased when Perospirone is combined with Pomalidomide.Approved
PerphenazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Pomalidomide.Approved
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Pomalidomide.Approved
PhenobarbitalThe metabolism of Pomalidomide can be increased when combined with Phenobarbital.Approved
PhenoxyethanolThe risk or severity of adverse effects can be increased when Phenoxyethanol is combined with Pomalidomide.Approved
PhenytoinThe metabolism of Pomalidomide can be increased when combined with Phenytoin.Approved, Vet Approved
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Pomalidomide.Approved, Investigational
PimozideThe serum concentration of Pomalidomide can be increased when it is combined with Pimozide.Approved
PipamperoneThe risk or severity of adverse effects can be increased when Pipamperone is combined with Pomalidomide.Approved
PipotiazineThe risk or severity of adverse effects can be increased when Pipotiazine is combined with Pomalidomide.Approved
PiritramideThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Piritramide.Investigational
PizotifenThe risk or severity of adverse effects can be increased when Pizotifen is combined with Pomalidomide.Approved
Platelet Activating FactorThe serum concentration of Pomalidomide can be decreased when it is combined with Platelet Activating Factor.Experimental
PonatinibThe serum concentration of Pomalidomide can be increased when it is combined with Ponatinib.Approved
PosaconazoleThe metabolism of Pomalidomide can be decreased when combined with Posaconazole.Approved, Investigational, Vet Approved
PramipexolePomalidomide may increase the sedative activities of Pramipexole.Approved, Investigational
PramocaineThe risk or severity of adverse effects can be increased when Pramocaine is combined with Pomalidomide.Approved
PravastatinThe serum concentration of Pomalidomide can be increased when it is combined with Pravastatin.Approved
PrazepamThe risk or severity of adverse effects can be increased when Prazepam is combined with Pomalidomide.Approved, Illicit
PrazosinThe serum concentration of Pomalidomide can be increased when it is combined with Prazosin.Approved
PrednisoneThe serum concentration of Pomalidomide can be increased when it is combined with Prednisone.Approved, Vet Approved
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Pomalidomide.Approved, Illicit, Investigational
PregnanoloneThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Pregnanolone.Investigational
PrilocaineThe risk or severity of adverse effects can be increased when Prilocaine is combined with Pomalidomide.Approved
PrimidoneThe metabolism of Pomalidomide can be increased when combined with Primidone.Approved, Vet Approved
ProbenecidThe serum concentration of Pomalidomide can be increased when it is combined with Probenecid.Approved
ProcaineThe risk or severity of adverse effects can be increased when Procaine is combined with Pomalidomide.Approved, Investigational, Vet Approved
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Pomalidomide.Approved, Vet Approved
ProgesteroneThe serum concentration of Pomalidomide can be decreased when it is combined with Progesterone.Approved, Vet Approved
PromazineThe risk or severity of adverse effects can be increased when Promazine is combined with Pomalidomide.Approved, Vet Approved
PromethazineThe serum concentration of Pomalidomide can be increased when it is combined with Promethazine.Approved
PropafenoneThe serum concentration of Pomalidomide can be increased when it is combined with Propafenone.Approved
ProparacaineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Pomalidomide.Approved, Vet Approved
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Pomalidomide.Approved, Investigational, Vet Approved
PropoxycaineThe risk or severity of adverse effects can be increased when Propoxycaine is combined with Pomalidomide.Approved
PropranololThe serum concentration of Pomalidomide can be increased when it is combined with Propranolol.Approved, Investigational
ProtriptylineThe serum concentration of Pomalidomide can be increased when it is combined with Protriptyline.Approved
PSD502The risk or severity of adverse effects can be increased when PSD502 is combined with Pomalidomide.Investigational
QuazepamThe risk or severity of adverse effects can be increased when Quazepam is combined with Pomalidomide.Approved, Illicit
QuercetinThe serum concentration of Pomalidomide can be increased when it is combined with Quercetin.Experimental
QuetiapineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Pomalidomide.Approved
QuinacrineThe serum concentration of Pomalidomide can be increased when it is combined with Quinacrine.Approved
QuinidineThe serum concentration of Pomalidomide can be increased when it is combined with Quinidine.Approved
QuinineThe serum concentration of Pomalidomide can be increased when it is combined with Quinine.Approved
Rabies vaccineThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Rabies vaccine.Approved
Rabies vaccineThe therapeutic efficacy of Rabies vaccine can be decreased when used in combination with Pomalidomide.Approved
RacloprideThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Raclopride.Investigational
RamelteonThe risk or severity of adverse effects can be increased when Ramelteon is combined with Pomalidomide.Approved, Investigational
RanitidineThe serum concentration of Pomalidomide can be increased when it is combined with Ranitidine.Approved
RanolazineThe serum concentration of Pomalidomide can be increased when it is combined with Ranolazine.Approved, Investigational
ReboxetineThe serum concentration of Pomalidomide can be increased when it is combined with Reboxetine.Approved, Investigational
RegorafenibThe serum concentration of Pomalidomide can be increased when it is combined with Regorafenib.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Pomalidomide.Approved
RemoxiprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Pomalidomide.Approved, Withdrawn
ReserpineThe serum concentration of Pomalidomide can be decreased when it is combined with Reserpine.Approved
RifabutinThe metabolism of Pomalidomide can be increased when combined with Rifabutin.Approved
RifampicinThe metabolism of Pomalidomide can be increased when combined with Rifampicin.Approved
RifapentineThe metabolism of Pomalidomide can be increased when combined with Rifapentine.Approved
RilpivirineThe serum concentration of Pomalidomide can be increased when it is combined with Rilpivirine.Approved
RisperidoneThe risk or severity of adverse effects can be increased when Risperidone is combined with Pomalidomide.Approved, Investigational
RitanserinThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Ritanserin.Investigational
RitonavirThe metabolism of Pomalidomide can be decreased when combined with Ritonavir.Approved, Investigational
RoflumilastRoflumilast may increase the immunosuppressive activities of Pomalidomide.Approved
RolapitantThe serum concentration of Pomalidomide can be increased when it is combined with Rolapitant.Approved
RomifidineThe risk or severity of adverse effects can be increased when Romifidine is combined with Pomalidomide.Vet Approved
RopinirolePomalidomide may increase the sedative activities of Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Pomalidomide.Approved
RotigotinePomalidomide may increase the sedative activities of Rotigotine.Approved
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Pomalidomide.Approved
S-EthylisothioureaThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Pomalidomide.Experimental
Sage 547The risk or severity of adverse effects can be increased when Pomalidomide is combined with Sage 547.Investigational
SaquinavirThe metabolism of Pomalidomide can be decreased when combined with Saquinavir.Approved, Investigational
ScopolamineThe serum concentration of Pomalidomide can be increased when it is combined with Scopolamine.Approved
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Pomalidomide.Approved, Vet Approved
SelegilineThe serum concentration of Pomalidomide can be increased when it is combined with Selegiline.Approved, Investigational, Vet Approved
SertindoleThe risk or severity of adverse effects can be increased when Sertindole is combined with Pomalidomide.Approved, Withdrawn
SertralineThe serum concentration of Pomalidomide can be increased when it is combined with Sertraline.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Pomalidomide.Approved, Vet Approved
SildenafilThe metabolism of Pomalidomide can be decreased when combined with Sildenafil.Approved, Investigational
SiltuximabThe serum concentration of Pomalidomide can be decreased when it is combined with Siltuximab.Approved
SimeprevirThe serum concentration of Pomalidomide can be increased when it is combined with Simeprevir.Approved
SimvastatinThe serum concentration of Pomalidomide can be increased when it is combined with Simvastatin.Approved
Sipuleucel-TThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Pomalidomide.Approved
SirolimusThe serum concentration of Pomalidomide can be decreased when it is combined with Sirolimus.Approved, Investigational
Sodium oxybateSodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Pomalidomide.Approved
SorafenibThe serum concentration of Pomalidomide can be increased when it is combined with Sorafenib.Approved, Investigational
SpironolactoneThe serum concentration of Pomalidomide can be increased when it is combined with Spironolactone.Approved
SRP 299The risk or severity of adverse effects can be increased when Pomalidomide is combined with SRP 299.Investigational
St. John's WortThe serum concentration of Pomalidomide can be decreased when it is combined with St. John's Wort.Nutraceutical
StaurosporineThe serum concentration of Pomalidomide can be increased when it is combined with Staurosporine.Experimental
StiripentolThe serum concentration of Pomalidomide can be increased when it is combined with Stiripentol.Approved
StreptozocinThe serum concentration of Pomalidomide can be decreased when it is combined with Streptozocin.Approved
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Pomalidomide.Approved, Investigational
SulfinpyrazoneThe serum concentration of Pomalidomide can be increased when it is combined with Sulfinpyrazone.Approved
SulfisoxazoleThe metabolism of Pomalidomide can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
SulpirideThe risk or severity of adverse effects can be increased when Sulpiride is combined with Pomalidomide.Approved
SumatriptanThe serum concentration of Pomalidomide can be increased when it is combined with Sumatriptan.Approved, Investigational
SunitinibThe serum concentration of Pomalidomide can be increased when it is combined with Sunitinib.Approved, Investigational
SuvorexantPomalidomide may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
TacrineThe serum concentration of Pomalidomide can be increased when it is combined with Tacrine.Withdrawn
TacrolimusThe risk or severity of adverse effects can be increased when Tacrolimus is combined with Pomalidomide.Approved, Investigational
TacrolimusThe serum concentration of Pomalidomide can be decreased when it is combined with Tacrolimus.Approved, Investigational
TamoxifenThe serum concentration of Pomalidomide can be decreased when it is combined with Tamoxifen.Approved
TandospironeThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Tandospirone.Investigational
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Pomalidomide.Approved
TasimelteonThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Tasimelteon.Approved
Taurocholic AcidThe serum concentration of Pomalidomide can be increased when it is combined with Taurocholic Acid.Experimental
TelaprevirThe metabolism of Pomalidomide can be decreased when combined with Telaprevir.Approved
TelithromycinThe metabolism of Pomalidomide can be decreased when combined with Telithromycin.Approved
TelmisartanThe serum concentration of Pomalidomide can be increased when it is combined with Telmisartan.Approved, Investigational
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Pomalidomide.Approved
TemsirolimusThe serum concentration of Pomalidomide can be increased when it is combined with Temsirolimus.Approved
TenofovirThe metabolism of Pomalidomide can be decreased when combined with Tenofovir.Approved, Investigational
TerazosinThe serum concentration of Pomalidomide can be increased when it is combined with Terazosin.Approved
TerfenadineThe serum concentration of Pomalidomide can be increased when it is combined with Terfenadine.Withdrawn
TeriflunomideThe serum concentration of Pomalidomide can be decreased when it is combined with Teriflunomide.Approved
TesmilifeneThe serum concentration of Pomalidomide can be decreased when it is combined with Tesmilifene.Investigational
TestosteroneThe serum concentration of Pomalidomide can be increased when it is combined with Testosterone.Approved, Investigational
TetrabenazineThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Pomalidomide.Approved
TetracaineThe risk or severity of adverse effects can be increased when Tetracaine is combined with Pomalidomide.Approved, Vet Approved
TetrodotoxinThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Pomalidomide.Investigational
TG4010The risk or severity of adverse effects can be increased when Pomalidomide is combined with TG4010.Investigational
ThalidomidePomalidomide may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational, Withdrawn
TheophyllineThe metabolism of Pomalidomide can be decreased when combined with Theophylline.Approved
ThiamylalThe risk or severity of adverse effects can be increased when Thiamylal is combined with Pomalidomide.Approved, Vet Approved
ThiopentalThe risk or severity of adverse effects can be increased when Thiopental is combined with Pomalidomide.Approved, Vet Approved
ThioridazineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Pomalidomide.Approved
ThiothixeneThe risk or severity of adverse effects can be increased when Thiothixene is combined with Pomalidomide.Approved
TiagabineThe risk or severity of adverse effects can be increased when Tiagabine is combined with Pomalidomide.Approved
TiaprideThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Tiapride.Investigational
TicagrelorThe serum concentration of Pomalidomide can be increased when it is combined with Ticagrelor.Approved
TiclopidineThe metabolism of Pomalidomide can be decreased when combined with Ticlopidine.Approved
TiletamineThe risk or severity of adverse effects can be increased when Tiletamine is combined with Pomalidomide.Vet Approved
TizanidineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Pomalidomide.Approved
TocilizumabThe serum concentration of Pomalidomide can be decreased when it is combined with Tocilizumab.Approved
TofacitinibPomalidomide may increase the immunosuppressive activities of Tofacitinib.Approved, Investigational
TolcaponeThe risk or severity of adverse effects can be increased when Tolcapone is combined with Pomalidomide.Approved, Withdrawn
TolvaptanThe serum concentration of Pomalidomide can be increased when it is combined with Tolvaptan.Approved
TopiramateThe risk or severity of adverse effects can be increased when Topiramate is combined with Pomalidomide.Approved
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Pomalidomide.Approved, Investigational
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Pomalidomide.Experimental
TranylcypromineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Pomalidomide.Approved
TrastuzumabTrastuzumab may increase the cardiotoxic activities of Pomalidomide.Approved, Investigational
TrazodoneThe serum concentration of Pomalidomide can be decreased when it is combined with Trazodone.Approved, Investigational
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Pomalidomide.Approved
TrifluoperazineThe serum concentration of Pomalidomide can be increased when it is combined with Trifluoperazine.Approved
TriflupromazineThe serum concentration of Pomalidomide can be increased when it is combined with Triflupromazine.Approved, Vet Approved
TrimethoprimThe serum concentration of Pomalidomide can be decreased when it is combined with Trimethoprim.Approved, Vet Approved
TrimipramineThe serum concentration of Pomalidomide can be increased when it is combined with Trimipramine.Approved
TriprolidineThe risk or severity of adverse effects can be increased when Triprolidine is combined with Pomalidomide.Approved
TroleandomycinThe serum concentration of Pomalidomide can be increased when it is combined with Troleandomycin.Approved
Uc1010The risk or severity of adverse effects can be increased when Pomalidomide is combined with Uc1010.Investigational
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Pomalidomide.Approved, Investigational
VemurafenibThe serum concentration of Pomalidomide can be increased when it is combined with Vemurafenib.Approved
VenlafaxineThe metabolism of Pomalidomide can be decreased when combined with Venlafaxine.Approved
VerapamilThe metabolism of Pomalidomide can be decreased when combined with Verapamil.Approved
VigabatrinThe risk or severity of adverse effects can be increased when Vigabatrin is combined with Pomalidomide.Approved
VinblastineThe serum concentration of Pomalidomide can be decreased when it is combined with Vinblastine.Approved
VincristineThe serum concentration of Pomalidomide can be decreased when it is combined with Vincristine.Approved, Investigational
VinorelbineThe serum concentration of Pomalidomide can be increased when it is combined with Vinorelbine.Approved, Investigational
VoriconazoleThe metabolism of Pomalidomide can be decreased when combined with Voriconazole.Approved, Investigational
VortioxetineThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Pomalidomide.Approved
XylazineThe risk or severity of adverse effects can be increased when Xylazine is combined with Pomalidomide.Vet Approved
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Pomalidomide.Approved, Illicit, Investigational
ZiconotideThe risk or severity of adverse effects can be increased when Ziconotide is combined with Pomalidomide.Approved
ZimelidineThe serum concentration of Pomalidomide can be increased when it is combined with Zimelidine.Withdrawn
ZiprasidoneThe metabolism of Pomalidomide can be decreased when combined with Ziprasidone.Approved
ZolazepamThe risk or severity of adverse effects can be increased when Zolazepam is combined with Pomalidomide.Vet Approved
ZolpidemPomalidomide may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ZonisamideThe risk or severity of adverse effects can be increased when Zonisamide is combined with Pomalidomide.Approved, Investigational
ZopicloneThe risk or severity of adverse effects can be increased when Zopiclone is combined with Pomalidomide.Approved
ZotepineThe risk or severity of adverse effects can be increased when Zotepine is combined with Pomalidomide.Approved
ZuclopenthixolThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Pomalidomide.Approved, Investigational
Food InteractionsNot Available
References
Synthesis ReferenceNot Available
General References
  1. Gertz MA: Pomalidomide and myeloma meningitis. Leuk Lymphoma. 2013 Apr;54(4):681-2. doi: 10.3109/10428194.2012.723708. Epub 2013 Jan 2. [PubMed:22917017 ]
  2. McCurdy AR, Lacy MQ: Pomalidomide and its clinical potential for relapsed or refractory multiple myeloma: an update for the hematologist. Ther Adv Hematol. 2013 Jun;4(3):211-6. doi: 10.1177/2040620713480155. [PubMed:23730498 ]
  3. Terpos E, Kanellias N, Christoulas D, Kastritis E, Dimopoulos MA: Pomalidomide: a novel drug to treat relapsed and refractory multiple myeloma. Onco Targets Ther. 2013 May 10;6:531-8. doi: 10.2147/OTT.S34498. Print 2013. [PubMed:23690693 ]
External Links
ATC CodesL04AX06
AHFS Codes
  • 10:00
PDB EntriesNot Available
FDA labelDownload (292 KB)
MSDSDownload (479 KB)
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9653
Blood Brain Barrier+0.8304
Caco-2 permeable-0.6419
P-glycoprotein substrateSubstrate0.5264
P-glycoprotein inhibitor INon-inhibitor0.5983
P-glycoprotein inhibitor IINon-inhibitor0.9147
Renal organic cation transporterNon-inhibitor0.847
CYP450 2C9 substrateNon-substrate0.844
CYP450 2D6 substrateNon-substrate0.8882
CYP450 3A4 substrateSubstrate0.5079
CYP450 1A2 substrateNon-inhibitor0.8863
CYP450 2C9 inhibitorNon-inhibitor0.8428
CYP450 2D6 inhibitorNon-inhibitor0.9002
CYP450 2C19 inhibitorNon-inhibitor0.8513
CYP450 3A4 inhibitorNon-inhibitor0.7289
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8686
Ames testNon AMES toxic0.7979
CarcinogenicityNon-carcinogens0.9081
BiodegradationNot ready biodegradable0.9858
Rat acute toxicity2.5862 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9885
hERG inhibition (predictor II)Non-inhibitor0.7765
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage forms
FormRouteStrength
CapsuleOral1 mg
CapsuleOral1 mg/1
CapsuleOral2 mg/1
CapsuleOral2 mg
CapsuleOral3 mg/1
CapsuleOral3 mg
CapsuleOral4 mg/1
CapsuleOral4 mg
PricesNot Available
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US5635517 No1996-07-242016-07-24Us
US6045501 No1998-08-282018-08-28Us
US6315720 No2000-10-232020-10-23Us
US6316471 No1996-08-102016-08-10Us
US6476052 No1996-07-242016-07-24Us
US6561976 No1998-08-282018-08-28Us
US6561977 No2000-10-232020-10-23Us
US6755784 No2000-10-232020-10-23Us
US6908432 No1998-08-282018-08-28Us
US8158653 No1996-08-102016-08-10Us
US8198262 No2004-10-192024-10-19Us
US8204763 No1998-08-282018-08-28Us
US8315886 No2000-10-232020-10-23Us
US8589188 No1998-08-282018-08-28Us
US8626531 No2000-10-232020-10-23Us
US8673939 No2003-05-152023-05-15Us
US8735428 No2003-05-152023-05-15Us
US8828427 No2011-06-212031-06-21Us
Properties
StateSolid
Experimental PropertiesNot Available
Predicted Properties
PropertyValueSource
Water Solubility2.57 mg/mLALOGPS
logP0.02ALOGPS
logP-0.16ChemAxon
logS-2ALOGPS
pKa (Strongest Acidic)11.59ChemAxon
pKa (Strongest Basic)1.56ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area109.57 Å2ChemAxon
Rotatable Bond Count1ChemAxon
Refractivity69.03 m3·mol-1ChemAxon
Polarizability25.81 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
SpectraNot Available
Taxonomy
ClassificationNot classified

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Metal ion binding
Specific Function:
Substrate recognition component of a DCX (DDB1-CUL4-X-box) E3 protein ligase complex that mediates the ubiquitination and subsequent proteasomal degradation of target proteins, such as MEIS2. Normal degradation of key regulatory proteins is required for normal limb outgrowth and expression of the fibroblast growth factor FGF8. May play a role in memory and learning by regulating the assembly an...
Gene Name:
CRBN
Uniprot ID:
Q96SW2
Molecular Weight:
50545.375 Da
References
  1. McCurdy AR, Lacy MQ: Pomalidomide and its clinical potential for relapsed or refractory multiple myeloma: an update for the hematologist. Ther Adv Hematol. 2013 Jun;4(3):211-6. doi: 10.1177/2040620713480155. [PubMed:23730498 ]
  2. Ito T, Ando H, Suzuki T, Ogura T, Hotta K, Imamura Y, Yamaguchi Y, Handa H: Identification of a primary target of thalidomide teratogenicity. Science. 2010 Mar 12;327(5971):1345-50. doi: 10.1126/science.1177319. [PubMed:20223979 ]
  3. Lopez-Girona A, Mendy D, Ito T, Miller K, Gandhi AK, Kang J, Karasawa S, Carmel G, Jackson P, Abbasian M, Mahmoudi A, Cathers B, Rychak E, Gaidarova S, Chen R, Schafer PH, Handa H, Daniel TO, Evans JF, Chopra R: Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide. Leukemia. 2012 Nov;26(11):2326-35. doi: 10.1038/leu.2012.119. Epub 2012 May 3. [PubMed:22552008 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Tumor necrosis factor receptor binding
Specific Function:
Cytokine that binds to TNFRSF1A/TNFR1 and TNFRSF1B/TNFBR. It is mainly secreted by macrophages and can induce cell death of certain tumor cell lines. It is potent pyrogen causing fever by direct action or by stimulation of interleukin-1 secretion and is implicated in the induction of cachexia, Under certain conditions it can stimulate cell proliferation and induce cell differentiation. Impairs ...
Gene Name:
TNF
Uniprot ID:
P01375
Molecular Weight:
25644.15 Da
References
  1. Gertz MA: Pomalidomide and myeloma meningitis. Leuk Lymphoma. 2013 Apr;54(4):681-2. doi: 10.3109/10428194.2012.723708. Epub 2013 Jan 2. [PubMed:22917017 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Prostaglandin-endoperoxide synthase activity
Specific Function:
Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Constitutively expressed in some tissues in physiological conditions, such as the endothelium, kidney and brain, and in pathological conditions, such as in cancer. PTGS2 is responsible for production of inflammatory prostaglandins. Up-regulation of PTGS2 is also associated with increased cell adhesion, p...
Gene Name:
PTGS2
Uniprot ID:
P35354
Molecular Weight:
68995.625 Da
References
  1. Ferguson GD, Jensen-Pergakes K, Wilkey C, Jhaveri U, Richard N, Verhelle D, De Parseval LM, Corral LG, Xie W, Morris CL, Brady H, Chan K: Immunomodulatory drug CC-4047 is a cell-type and stimulus-selective transcriptional inhibitor of cyclooxygenase 2. J Clin Immunol. 2007 Mar;27(2):210-20. Epub 2007 Feb 17. [PubMed:17308870 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Most active in catalyzing 2-hydroxylation. Caffeine is metabolized primarily by cytochrome CYP1A2 in the liver through an initial N...
Gene Name:
CYP1A2
Uniprot ID:
P05177
Molecular Weight:
58293.76 Da
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:
ABCB1
Uniprot ID:
P08183
Molecular Weight:
141477.255 Da
Comments
comments powered by Disqus
Drug created on June 20, 2013 16:45 / Updated on December 10, 2016 02:41